Orum Therapeutics KRX:475830KOSDAQ
오름테라퓨틱 · Korean news coverage and regulatory filings, organized.
Articles, 24h2
Articles, 7 days2
DART filings, 7 days2
Articles tracked2since Sep 11
In Q2 2026, Orum Therapeutics reported revenue of ₩24m, up 479.1% year on year, and an operating loss of ₩15.4bn. Orum Therapeutics (오름테라퓨틱) appeared in 2 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Sep 15 with 2 articles. It was most often mentioned alongside Nextbiomedical, Dentium and Qurient.
Orum Therapeutics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩24m | +479.1% | −₩15.4bn | ₩63.4bn |
| Q1 2026 | ₩0m | -100.0% | −₩18.1bn | −₩15.3bn |
| Q4 2025 derived | ₩1m | -77.5% | −₩18.3bn | −₩16.0bn |
| Q3 2025 | ₩16m | – | −₩13.9bn | −₩13.6bn |
| Q2 2025 | ₩4m | -74.3% | −₩10.0bn | −₩3.8bn |
| Q1 2025 | ₩3m | -80.9% | −₩9.6bn | −₩8.6bn |
| Q4 2024 derived | ₩2m | – | −₩7.9bn | −₩10.9bn |
| Q3 2024 check units | ₩20.9bn | – | ₩12.8bn | ₩14.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Orum Therapeutics top stories 2 weeks, by number of outlets
- 1
- 2
